Interesting live Session on Transthyretin Amyloid Cardiomyopathy (ATTR-CM) by Pf

Speciality: Cardiology

Description:

A warm welcome to all the medical professionals in this interesting session on understanding the management of ATTRCM with the use of Vyndamax. 

ATTR-CM is a protein deposition disorder that affects the heart, leading to structural damage and heart failure. It can be classified as wild type ATTR-CM or hereditary ATTR-CM.

Diagnostic tools like scintigraphy and hematologic tests are essential for confirming the diagnosis of ATTR-CM. Scintigraphy helps visualize the extent of amyloid deposition, while hematologic tests detect monoclonal proteins.

Vyndamax, a drug by Pfizer, has shown promising results in the treatment of ATTR-CM. It stabilizes the protein and prevents further amyloid deposition, improving patient outcomes and reducing mortality.

Therefore,  get an overall knowledge regarding understanding the importance of Tafamidis drug in controlling ATTRCM. Listen to the webinar, grab the knowledge that is shared, and follow HiDoc for more such interesting webinar sessions.
 

See More Webinars @ Hidoc Webinars